BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported Q2 2017 earnings this Afternoon, coming in at ($0.21) per share, in-line Wall Street’s estimates of ($0.21) per Share. Revenue for the quarter came in at $317.50 million beating analyst estimates of $311.41 million
Analyst Coverage For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
These are 7 Hold Ratings, 13 Buy Ratings .
The current consensus rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is Buy (Score: 2.65) with a consensus target price of $111.83 , a potential (27.61% upside)Recent Insider Trading for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
- On 6/23/2017 George Eric Davis, EVP, sold 9,844 with an average share price of $96.60 per share and the total transaction amounting to $950,930.40.
- On 6/22/2017 Brian Mueller, SVP, sold 2,671 with an average share price of $100.00 per share and the total transaction amounting to $267,100.00.
- On 6/19/2017 Henry J Fuchs, Insider, sold 15,000 with an average share price of $90.00 per share and the total transaction amounting to $1,350,000.00.
- On 6/16/2017 V Bryan Lawlis, Director, sold 3,750 with an average share price of $90.00 per share and the total transaction amounting to $337,500.00.
- On 6/7/2017 Jeffrey Robert Ajer, EVP, sold 1,004 with an average share price of $89.61 per share and the total transaction amounting to $89,968.44.
- On 6/5/2017 George Eric Davis, EVP, sold 9,471 with an average share price of $91.04 per share and the total transaction amounting to $862,239.84.
Recent Trading for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares of BioMarin Pharmaceutical Inc. closed the previous trading session at 87.64 down -0.38 -0.43% with 1,676,971 shares trading hands.